Richard Levy
Directeur/Membre du Conseil chez MADRIGAL PHARMACEUTICALS, INC.
Fortune : 2 M $ au 30/04/2024
Profil
Richard S.
Levy is currently serving as a Non-Executive Director at Gliknik, Inc. since 2014, an Independent Director at Kiniksa Pharmaceuticals Ltd.
since 2019, an Independent Director at Madrigal Pharmaceuticals, Inc. since 2016, an Independent Director at Kodiak Sciences, Inc. since 2018, and an Independent Director at Protara Therapeutics, Inc. since 2019.
Previously, he held positions as an Independent Director at Aquinox Pharmaceuticals, Inc. from 2017 to 2019, an Independent Director at Constellation Pharmaceuticals, Inc. from 2020 to 2021, and as a Director at ArTara Subsidiary, Inc. He also served as the Vice President-Biologic Therapies at Celgene Corp.
from 2002 to 2003, the Chief Drug Development & Medical Officer and EVP at Incyte Corp.
from 2003 to 2016, and as the Vice President-Medical & Commercial Strategy at DuPont Pharmaceuticals Co. from 1997 to 2002.
Additionally, he worked as an Assistant Professor at the David Geffen School of Medicine.
Dr. Levy obtained his undergraduate degree from Brown University and doctorate degrees from the University of Pennsylvania and the Perelman School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 22/04/2024 | 10 298 ( 0,05% ) | 2 M $ | 30/04/2024 | |
| 03/05/2024 | 8 524 ( 0,02% ) | 150 108 $ | 30/04/2024 | |
| 11/04/2024 | 31 000 ( 0,27% ) | 94 550 $ | 30/04/2024 | |
KODIAK SCIENCES, INC.
0,00% | 01/04/2024 | 1 000 ( 0,00% ) | 3 185 $ | 30/04/2024 |
Postes actifs de Richard Levy
| Sociétés | Poste | Début |
|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 11/08/2016 |
| KODIAK SCIENCES INC. | Directeur/Membre du Conseil | 18/07/2018 |
| KINIKSA PHARMACEUTICALS, LTD. | Directeur/Membre du Conseil | 04/03/2019 |
| PROTARA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/12/2019 |
Gliknik, Inc.
 Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD. | Directeur/Membre du Conseil | 19/02/2014 |
Anciens postes connus de Richard Levy
| Sociétés | Poste | Fin |
|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/06/2021 |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Directeur/Membre du Conseil | 08/08/2019 |
| INCYTE CORPORATION | Directeur Technique/Scientifique/R&D | 30/04/2016 |
| CELGENE | Corporate Officer/Principal | 01/01/2003 |
| ░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Richard Levy
| Brown University | Undergraduate Degree |
| University of Pennsylvania | Doctorate Degree |
| Perelman School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| MADRIGAL PHARMACEUTICALS, INC. | Health Technology |
| KODIAK SCIENCES INC. | Health Technology |
| PROTARA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Gliknik, Inc.
Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD. | Health Technology |
DuPont Pharmaceuticals Co.
 DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Health Technology |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Sandoz Corp.
 Sandoz Corp. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Sandoz Corp. develops, produces, and markets medicines. | Health Technology |
ArTara Subsidiary, Inc.
 ArTara Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ArTara Subsidiary, Inc. engages in the research and development of specialty diseases therapeutics. Its programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology or gastrointestinal and metabolic disorders. The company was founded by Jesse Shefferman in 2017 and is headquartered in New York, NY. | Health Technology |